

# **Apex Medical Corp.**

## **2021 The First Investor Conference**

Apr. 15<sup>th</sup> , 2021

### **PEX** Year 2020 Consolidated Income Statement

Unit: NTDK

	Year 2020 Audited	Year 2019 Audited	<b>'20/'19</b> Var.(\$)	<b>'20/'19</b> Var.(%)
Net Sales	2,004,025	2,036,232	(32,207)	-2%
Gross Profit	847,631	853,817	(6,186)	-
Gross Margin(%)	42.3%	41.9%	-	-
Operating Expenses	748,696	725,054	23,642	3%
Income before Tax	124,843	128,426	(3,583)	-3%
Net Income attributed to owner of the parent company	104,588	87,921	16,667	19%
Basic EPS(NT\$)	1.04	0.87	-	-



Unit: NTDK

	2020/12/31 Audited 2019/12/31 Audited		Variar	/ariance	
	Amount	Amount	Amount	%	
Cash and cash equivalent	470,157	419,451	50,706	12%	
Current financial assets at fair value through profit or loss	35,154	0	35,154	-	
Amortized cost financial assets	118,142	363,610	(245,468)	-68%	
Accounts receivable	299,213	285,755	13,458	5%	
Inventories	376,205	350,817	25,388	7%	
Total current assets	1,405,183	1,485,379	(80,196)	-5%	
Investments accounted for using equity method	0	211,096	(211,096)	-100%	
Property, plant and equipment	785,171	657,969	127,202	19%	
Right-of-use asset	80,877	101,807	(20,930)	-21%	
Intangible Assets	701,672	432,380	269,292	62%	
Other non-current assets	770	73,472	(72,702)	-99%	
Total non-current assets	1,641,226	1,535,027	106,199	7%	
Total Assets	3,046,409	3,020,406	26,003	1%	

Note: Only important accounts are listed in the table.



### 2020/12/31 Consolidated Balance Sheet(2)


Unit: NTDK

	2020/12/31 Audited 2019/12/31 Audited Varianc		е	
	Amount	Amount	Amount	%
Short-term debt	184,784	401,493	(216,709)	-54%
Accounts payable and other payable*	366,305	256,320	109,985	43%
Other current liabilities*	106,860	58,357	48,503	83%
Long-term debt – current	9,512	5,972	3,540	59%
Total current liabilities	709,855	753,513	(43,658)	-6%
Long-term debt	165,424	153,363	12,061	8%
Lease liabilities	55,871	73,626	(17,755)	-24%
Total long-term liabilities	230,271	236,914	(6,643)	-3%
Total liabilities	940,126	990,427	(50,301)	-5%
Total share capital	1,009,116	1,009,116	0	0%
Additional paid-in capital	345,635	345,635	0	0%
Total retained earnings	908,479	849,805	58,674	7%
Other equity	(161,517)	(178,568)	17,051	-10%
Owners' equity attributed to the parent company	2,101,713	2,025,988	75,725	4%
Total owners' equity	2,106,283	2,029,979	76,304	4%
Total liabilities and owners' equity	3,046,409	3,020,406	26,003	1%

Note: Only important accounts are listed in the table ; \*the accounts payable and other payable including the amount belong to the related parties.




#### **Sales by Department**





### **Sales by Product**





### **Operating Status or Events(1)**

The per book consolidated revenue for the first quarter of 2021 totaled NT\$ 581 million, up 39 percent compared to the same quarter of NT\$417 million last year.

本資料由	(上市公司) 雅博	公司提供
------	-----------	------

民國110年03月

單位:新台幣仟元

項目	營業收入淨額
本月	238,995
去年同期	180,291
増減金額	58,704
増減百分比	32.56
本年累計	580,864
去年累計	417,063
増減金額	163,801
増減百分比	39.27
備註/營收變化原因說明	



### **Operating Status or Events(2)**

Apex is awarded the 29<sup>th</sup> Taiwan Excellence Gold Award for the product of WiZARD 510 CPAP Mask in November, 2020.





### **Operating Status or Events(3)**

 In year 2021, we will launch 'Pro-care Optima Prone,' 'Pro-care Auto Pediatric' and other new products.





### http://www.apexmedicalcorp.com

#### IR@apexmedicalcorp.com